Lower radiation dose to tumor area for early nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of nasopharyngeal cancer called non-keratinizing (WHO type II or III).
- Your cancer is stage I to IVa, meaning it has not spread to distant parts of the body.
- The tumor in your nasopharynx is only on one side and does not cross the midline (confirmed by scope and MRI).
- Your doctor plans to give you curative radiation (IMRT), possibly with chemotherapy depending on your stage.
- You have not had previous cancer treatment (except for certain minor cancers).
- You are 18 to 70 years old and your general health and organ function are good (Karnofsky score 70 or above).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
This trial compares two approaches for people with early-stage nasopharyngeal cancer that can be removed with surgery. It tests whether giving less intense chemotherapy and radiation after surgery works as well as a standard dose, with fewer side effects.
This trial tests a new type of radiation therapy that adjusts in real-time to treat nasopharyngeal cancer. It is for people who have not received prior radiation and have no distant spread of cancer.
This trial tests whether giving a lower dose of radiation to the main tumor is safe and effective for people with nasopharyngeal cancer (a type of nose/throat cancer) who first receive a combination of immunotherapy (toripalimab) and chemotherapy. It aims to reduce side effects while still controlling the cancer.
This Phase 3 study tests whether giving a reduced amount of radiotherapy can work as well as the standard dose for certain people with stage II–III nasopharyngeal cancer who respond well after initial chemotherapy. It’s designed for patients whose cancer markers improve after 3 chemotherapy cycles, to potentially reduce treatment side effects while keeping cancer control.
This trial tests if lowering the radiation dose and area for the neck can be as effective as standard treatment for nasopharyngeal cancer. It aims to reduce side effects while still controlling the disease.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.